Related Experiment Videos
Translational and clinical studies of target-based cancer therapy
Nagahiro Saijo1, Kazuto Nishio, Tomohide Tamura
1National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Abstract:
The increasing number of negative trials in cancer treatment has prompted a systematic re-evaluation of target-based drugs. It is our impression that the sensitivity of current clinical trial methodology is inadequate to demonstrate the effectiveness of target-based drugs, in terms of tumor shrinkage, delay in progression, or improved survival. Enrichment of sensitive populations, based on the data from translational studies, is essential for a better understanding of the role of novel therapies in cancer. Translational and clinical studies are key to the identification and maximization of benefit of target-based therapy
Insights
Current cancer drug trials may not be sensitive enough to show effectiveness. Enriching patient populations using translational studies is crucial for understanding novel cancer therapies and maximizing patient benefit.
Area of Science:
- Oncology
- Translational Medicine
- Clinical Trial Design
Background:
- A growing number of cancer treatment trials yield negative results, necessitating a re-evaluation of target-based drugs.
- Existing clinical trial methodologies may lack the sensitivity to adequately detect the efficacy of target-based therapies, including tumor shrinkage, progression delay, or survival benefits.
Purpose of the Study:
- To highlight the inadequacy of current clinical trial sensitivity for target-based cancer drugs.
- To emphasize the importance of patient population enrichment in assessing novel cancer therapies.
- To underscore the critical role of translational and clinical studies in optimizing target-based treatment benefits.
Main Methods:
- Systematic re-evaluation of target-based cancer drug trials.
- Analysis of clinical trial sensitivity in detecting treatment efficacy.
- Review of translational studies for patient population enrichment strategies.
Main Results:
- Current clinical trial methods are insufficient to demonstrate the effectiveness of target-based drugs.
- Enriching patient populations based on translational data is essential for evaluating novel therapies.
- Target-based therapies require refined methodologies for benefit assessment.
Conclusions:
- Enhanced sensitivity in clinical trial design is imperative for target-based cancer drug evaluation.
- Translational studies are vital for identifying patient subgroups most likely to benefit from novel therapies.
- Optimizing the use of target-based therapies depends on robust translational and clinical research.